Evidence map›Paper›PMID 32850911›Full record

ArticleFrontiers in medicine2020

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade

Laixi Xue, K van Bilsen, M W J Schreurs, M E J van Velthoven, T O Missotten, A A H J Thiadens, R W A M Kuijpers, P van Biezen, V A S H Dalm, J A M van Laar and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026
    Review
  4. Advances in the Treatment of Behcet's Disease.Current rheumatology reports · 2021
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Laixi XueInternal Medicine, Erasmus University Rotterdam, Rotterdam, Netherlands.
K van BilsenDepartment of Internal Medicine, Division of Clinical Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
M W J SchreursAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
M E J van VelthovenAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
T O MissottenAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
A A H J ThiadensDepartment of Ophthalmology, Erasmus MC, University Medical Centre, Rotterdam, Netherlands.
R W A M KuijpersDepartment of Ophthalmology, Erasmus MC, University Medical Centre, Rotterdam, Netherlands.
P van BiezenAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
V A S H DalmAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
J A M van LaarAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
M A W HermansAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
W A DikAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
P L A van DaeleAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
P M van HagenAcademic Center for Rare Immunological Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Erasmus MC · NLErasmus University Rotterdam · NLAlbert Schweitzer Ziekenhuis · NLSpaarne Gasthuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-TNF-alphabiosimilarCTP 13fucosylationinfliximabrare or orphan immune-mediated inflammatory diseases (IMIDs)Remicade®Remsima®

Identifiers

PMID32850911
PMCPMC7424016
OpenAlexW3042481399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.